Tumor Tips

Tumor Tip of the Week 03-06-2026 Invasive Breast, Neoadjuvant, DCIS

03-06-2026 Invasive Breast, Neoadjuvant, DCIS

Scenario #1:

    • Screening digital mammogram with CAD with 3D bilateral-Technique: The following mammographic views were obtained: bilateral CC and MLO views were obtained in 2D and 3D (Digital Breast Tomosynthesis) -calcifications left breast 3:00 BI-RADS 0
    • Needle bx: Invasive ductal Carcinoma, G3, Her2+, ER-, PR-
    • MRI: Clumped non mass enhancement lt entire upper outer breast measuring 6.4cm extending to chest wall. No lad
    • Med Onc staged as cT1a cN0 cM0, treated with Neoadjuvant Taxol, Pertuzumab and Trastuzumab
    • Bilateral Simple Mastectomy w/ SLN bx w/o reconstruction

Question: How would you assign the ypT category?

  • ypT0
  • ypTis
  • ypTX
  • ypT Blank

Answer: ypTis

Rationale: There was no residual invasive carcinoma, however there was 10mm of residual DCIS, Nuclear Grade III

Some other fields to consider:

Field(s)

Result

Resources

yp Stage:

 

ypTis

ypN1a (sn) cM0

AJCC 8th Edition Chapter 48

yp Grade H

H

Grade Manual v3.3 Note 3: Assign the highest grade from the resected primary tumor assessed after the completion of neoadjuvant therapy

Residual Cancer Burden (RBC)

 

1

*New SSDI 2026+ Only record the information from the CAP Protocol or synoptic pathology report-SSDI Manual v 3.3

Residual Cancer Burden (RBC) Class

1.205

*New SSDI 2026+Only record the information from the CAP Protocol or synoptic pathology report-SSDI Manual v 3.3

Method of Detection for Breast Primary (NCDB Custom Data Item)

02

*New Data Items required for cases with diagnosis year 2026+

[COC Facilities ONLY]-STORE 2026

Related Content

Blog

[get_education_types]

Tumor Tip of the Week-04-17-2026 Where in the Small Intestine is that?

Blog

[get_education_types]

Tumor Tip of the Week 04-10-2026 Totally RAD News: SEER and CoC Back in Sync on PI RADS and LI RADS Coding

Blog

[get_education_types]

Tumor Tip of the Week 04-03-2026 To Be Ambiguous or Not To Be Ambiguous

Contact Us

Contact us today to learn how our technology-led, clinically enabled solutions can help your organization thrive.